"There is little defense against such analysis and it certainly will come. This is one possibility where our recent gains could be pushed back to the high 5's. Betting that the company has been "pocketing" substantial, measurable, criteria-based, positive results, and will now announce them, seems a weak bet."
Remember this is a Ph 1 trial with safety its primary goal! The efficacy party should be left for Ph2 to achieve.
"The other scenario that would put us back in the 5's is if the DCVax-L trial were to receive anything less than a stop for stat sig results at the long delayed, first interim. This interim could be reached at anytime. We have all touted DCVax as a mega treatment in the making. If there is a tear in Superman's suit, watch for the fallout."
I will agree with your above statement if the number 5's is changed to 10's or even 20's!
Strictly on stock price, it is just a battle now between longs and shorts, and things may finally come in our favor due to increased institutional interests and the L trial is just on the cusp of knowing the result!